Jin Zhe, Xin Zhong-cheng
Andrology Center, Peking University First Hospital, Beijing 100034, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2011 Aug 18;43(4):632-5.
Lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH/LUTS) and erectile dysfunction (ED) are common conditions seen in aging males. Although the exact mechanism of ED combined BPH/LUTS is unknown, treatment with α-adrenergic receptor resistance agents (α-ARAs) contributes to some improvement in ED, and phosphodiesterase-5 inhibitors (PDE-5I) are also of benefit to BPH/LUTS. The action mechanisms of these medications support these observed benefits, which are being studied in the basic science and clinical settings. Much remains to be investigated, but it is clear that the associations between BPH/LUTS and ED lay the foundation for future therapies and possible preventative strategies. This article has mainly summarized the advancement of epidemiology, basic research and treatment of ED combined with BPH/LUTS with α-receptor blockers and phosphodiesterase-5 inhibitors.
良性前列腺增生继发下尿路症状（BPH/LUTS）和勃起功能障碍（ED）是老年男性的常见病症。虽然ED合并BPH/LUTS的确切机制尚不清楚，但使用α-肾上腺素能受体阻滞剂（α-ARAs）治疗有助于ED的一定改善，磷酸二酯酶-5抑制剂（PDE-5I）对BPH/LUTS也有益处。这些药物的作用机制支持了所观察到的益处，目前正在基础科学和临床环境中进行研究。仍有许多有待研究，但很明显，BPH/LUTS与ED之间的关联为未来的治疗和可能的预防策略奠定了基础。本文主要总结了ED合并BPH/LUTS的流行病学进展、基础研究以及使用α受体阻滞剂和磷酸二酯酶-5抑制剂的治疗情况。
